Device Trial Radar · NCT02997553
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
744
Actual
Start
Nov 29, 2017
Primary completion
Sep 19, 2022
Study completion Oct 12, 2022
Sponsor
- Lead sponsor
- Institut de Cancérologie de LorraineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center prospective clinical trial to evaluate non-inferiority of indocyanine green guided sentinel lymph node biopsy compared with the gold standard Technecium99 guided sentinel lymph node biopsy in patients with cancers and subjected to surgery. The diagnostic performance and the tolerance of indocyanine green (ICG) to the radio-isotope (Techniciun99) in the detection of sentinel lymph nodes will be assess using an "Optonuclear" probe (EURORAD S.A.) and QUEST camera
Conditions
- Breast Carcinoma
- Head and Neck Cancer
- Melanoma (Skin)
- Squamous Cell Carcinoma, Skin
- Cervix Cancer
- Endometrium Cancer
- Ovary Cancer
- Vulva Cancer
- Anus Cancer
- Rectum Cancer
Interventions
Indocyanine greenDrug
Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
Technetium99Drug
Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery. Lymphoscintigraphy is performed to identify the sentinel node
Optonuclear probeDevice
The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
Quest CameraDevice
The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Non-inferiority of indocyanine green guided sentinel lymph node biopsyTime frame: 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.